Safety, Immunogenicity, and Immune Persistence Study of an Inactivated Hepatitis A Vaccine

Phase 4

Completed

• Conditions: Hepatitis A
• Interventions: Biological: Healive® Lot 1; Biological: Healive® Lot 2; Biological: Healive® Lot 3; Biological: Havrix

• Registration Number: NCT00534885
• Lead Sponsor: Sinovac Biotech Co., Ltd

Brief Summary

A double-blind, randomized and controlled clinical trial was conducted in healthy children aged from 1 to 8 years to evaluate the immunogenicity and safety of three consecutive lots of a preservative-free inactivated hepatitis A vaccine (Healive®).

Participants who completed their primary vaccination were invited to participate in the follow-up phase. Written informed consents were obtained from them. The follow-up study was open-label. These subjects were visited in the next 11 years for blood sampling and assessment of immune persistence induced by vaccination.

Detailed Description

The investigated vaccine is an inactivated, adjuvanted and preservative-free hepatitis A vaccine. Each dose contained 250 U HAV antigen in 0.5 milliliter.

Total 400 subjects were enrolled and assigned into four groups, each receiving one of the three lots of Healive® or an established control vaccine at month 0 and 6. Anti-HAV titers were determined at month 1, 6 and 7. Anti-HAV titer over 20 mIU/ml is defined as seroprotection.

After the full immunization schedule, written informed consents were obtained from subjects who would like to participate in the follow-up study. Blood samples of these subjects were collected at month 18, 30, 42, 54, 66, 112,138 after the first injection to evaluate the seroconversion rates (SCRs) and geometric mean concentrations (GMCs) of antibody against hepatitis A virus. Serological results of the follow-up study were then used to explore suitable statistical model for predicting the persistence of hepatitis A vaccine-induced antibodies.

Study Timeline

• Study Start: 2006-03
• Study First Submitted: 2007-09-24
• Study First Submitted QC: 2007-09-24
• Study First Posted: 2007-09-26
• Primary Completion: 2017-10
• Study Completion: 2017-10
• Status Verified: 2019-08
• Last Update Submitted: 2019-08-29
• Last Update Posted: 2019-09-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 400

Inclusion Criteria

• Health children from 1 to 10 years
• Not participate in any other trial during the course of the trial
• Informed consent

Exclusion Criteria

• Any history of allergic reactions or convulsions following vaccination
• Other known or planned vaccination within 1 month prior to the study and during the study period
• Any chronic illness/disease including virus hepatitis, tuberculosis and epilepsy
• Presence of any congenital abnormality, upgrowth obstacle
• Any history/suspicion/presence of neurology and Lunacy
• Any current or foreseeable use of immunosuppressors (i.e. corticosteroids , immunoglobulins) within 1 month prior to the vaccination and during the period of the study
• Contraindication to intramuscularly injection due to thrombocytopenia or other bleeding disorders
• Abnormal ALT
• Positive markers for anti-HAV and HBV（HBsAg）infection
• Presence of fever at the time of vaccination, i.e. body temperature (by mouth) > 37.0 centigrade.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
1: Healive® Lot 1	Healive® Lot 1	-
2: Healive® Lot 2	Healive® Lot 2	-
3: Healive® Lot 3	Healive® Lot 3	-
4: control vaccine (Havrix)	Havrix	-

Primary Outcome Measures

Name	Time	Method
Anti-HAV titer	7 months after the first dose	To evaluate the immune responses to the inactivated hepatitis A vaccine by detecting the anti-HAV titer using microparticle enzyme immunoassay (MEIA) assay.

Secondary Outcome Measures

Name	Time	Method
Solicited adverse reactions (AE): local reactions and systematic reactions	72 hours after each injection	Solicited AEs were recorded until 72 hours after each injection
Unsolicited adverse reactions (AE)	7 months after the first dose	Unsolicited AEs were recorded until month 7
Change of anti-HAV titer: geometry mean titer(GMT) and seroconversion rate	baseline (day 0), month 1, 6, 7, 18, 30, 42, 54, 66,112,138 after the first dose	Blood samples were collected at day 0, month 1, 6, 7, 18, 30, 42, 54, 66,112, 138 after the first dose to assess the change of long-term immune response. Anti-HAV antibodies were assessed by microparticle enzyme immunoassay (MEIA) assay (cut off: 20 mIU/ml)

Trial Locations

Locations (1)

Changzhou City Center for Disease Control and Prevention; 🇨🇳 Changzhou, Jiangsu, China